In a significant triumph for the Broad Institute of MIT and Harvard, three of its distinguished scientists have been recognized by the National Institutes of Health (NIH) for their bold, unconventional approaches to biomedical research. Erin Chen and Sam Peng have been awarded the prestigious NIH Director’s New Innovator Award, while JT Neal has been honored with the NIH Director’s Transformative Research Award.
These accolades are part of the NIH’s High-Risk, High-Reward Research Program, a competitive initiative designed to support exceptionally creative scientists who propose innovative projects that possess the potential to fundamentally shift current scientific paradigms. Chen, Peng, and Neal are among a cohort of 58 researchers nationwide receiving over $237 million in funding this year to tackle some of the most complex challenges in human health.
The Vanguard of Innovation: Profiles in Excellence
The selection of these three Broad Institute members underscores the institution’s commitment to interdisciplinary research that bridges the gap between basic discovery and clinical application.
Erin Chen: Decoding the Microbiome-Immune Axis
Dr. Erin Chen, who joined the Broad as a core institute member in 2023, occupies a unique space at the intersection of dermatology, immunology, and microbiology. As an assistant professor of biology at MIT and an attending dermatologist at Massachusetts General Hospital, Dr. Chen’s work is deeply informed by both the lab bench and the patient bedside.
Her New Innovator Award will provide the financial runway to explore the complex relationship between the skin microbiome and the human immune system. Specifically, her research focuses on how commensal bacteria residing on the skin surface influence T cell responses. By decoding the molecular signals that allow these bacteria to stimulate the immune system without inducing harmful inflammation, Dr. Chen hopes to pave the way for a new generation of immunotherapies. This work holds profound promise for treating inflammatory skin conditions and potentially harnessing the microbiome to combat cancer.
Sam Peng: Visualizing the Language of Cells
Dr. Sam Peng, a core institute member who arrived at the Broad in 2022, is an assistant professor of chemistry at MIT whose work centers on the invisible machinery of life. His research addresses the mechanisms of G-protein-coupled receptors (GPCRs), the largest family of cell-surface receptors in the human genome.
GPCRs serve as the body’s primary communication hubs, translating external signals from hormones and neurotransmitters into internal cellular responses. Despite their ubiquity—and their role as targets for a vast percentage of current pharmaceuticals—the real-time mechanics of how these receptors function remain elusive. Dr. Peng’s New Innovator Award will fund the development of pioneering single-molecule microscopy techniques. These tools will allow researchers to observe GPCR signaling pathways with unprecedented resolution, providing the structural insights necessary to design more effective, precision-targeted therapeutics for diseases ranging from cardiovascular disorders to neurological conditions.
JT Neal: Scaling the Search for Rare Disease Cures
Dr. JT Neal, an institute scientist and director of systems genomics at the Broad, is no stranger to NIH recognition, having received a New Innovator Award in 2021. His latest achievement, the Transformative Research Award, marks a significant escalation in his mission to translate genomic data into actionable medicine.
Dr. Neal’s career at the Broad has been defined by his development of massively parallel functional genomics and single-cell imaging technologies. His current project, titled "Encore," aims to solve a bottleneck in drug discovery for rare genetic diseases. By creating an experimental and computational platform that can screen thousands of drugs against hundreds of disease-associated phenotypes simultaneously, the project aims to test over 1.6 million drug-disease combinations. This high-throughput approach is designed to identify candidate therapies for rare, often neglected, genetic conditions at a speed and scale previously thought impossible.
Chronology of Recognition: A Legacy of Bold Science
The NIH High-Risk, High-Reward program was established to address the "valley of death" in scientific funding, where high-impact ideas that lack preliminary data often struggle to find support through traditional grants.
- 2021: JT Neal receives the NIH Director’s New Innovator Award, signaling the NIH’s early investment in his work on functional genomics and immuno-oncology modeling.
- 2022: Sam Peng joins the Broad Institute, bringing his expertise in physical chemistry and single-molecule dynamics to the scientific community.
- 2023: Erin Chen joins the Broad, further strengthening the institute’s focus on the intersection of microbial biology and immunology.
- 2024: The NIH announces the latest cohort of High-Risk, High-Reward recipients, officially honoring Chen, Peng, and Neal for their recent project proposals.
This trajectory reflects the Broad Institute’s strategic investment in talent that can traverse traditional departmental boundaries, allowing for the kind of "unconventional" science the NIH is currently prioritizing.
Supporting Data: Why High-Risk, High-Reward Matters
The $237 million allocated by the NIH Common Fund is not merely a financial grant; it is an endorsement of a specific scientific philosophy. Data from the NIH suggests that traditional grant mechanisms often favor "incremental" research—projects with high likelihoods of success but lower potential for paradigm shifts.
The High-Risk, High-Reward program tracks several key metrics to ensure its impact:
- Innovation Index: Projects are evaluated on their ability to overturn existing dogmas or introduce entirely new methodological frameworks.
- Breadth of Impact: The NIH prioritizes research that provides cross-disciplinary utility, such as Dr. Neal’s Encore platform, which is designed for broad application across multiple rare disease classes.
- Translational Readiness: While these projects are speculative, the NIH requires a clear roadmap for how these findings will eventually transition from the lab to clinical or commercial development.
For the Broad Institute, the success of these three researchers demonstrates the efficacy of the "Broad model"—a collaborative environment that provides the physical and computational infrastructure necessary to support high-stakes, high-complexity experimentation.
Official Responses and Perspectives
The leadership at both the Broad Institute and the NIH has lauded the achievements of these three scientists. While the NIH has emphasized the necessity of supporting "bold" science to solve the increasingly complex nature of human disease, Broad Institute leadership notes that these awards reflect the cultural emphasis placed on intellectual risk-taking.
"The work being done by Erin, Sam, and JT exemplifies the spirit of scientific discovery that we strive to foster," said a spokesperson for the Broad Institute. "They are not asking small questions; they are looking for the fundamental mechanisms that govern health and disease, and they are building the tools necessary to unlock those secrets."
Dr. Monica Bertagnolli, Director of the NIH, stated in a press release accompanying the announcement, "The breadth of these projects is truly remarkable. We are funding everything from the molecular underpinnings of cellular signaling to massive, AI-driven drug discovery platforms. These researchers are pushing the boundaries of what is known."
Implications for the Future of Medicine
The implications of these three projects extend far beyond the laboratory walls.
1. The Microbiome as a Therapeutic Frontier
Dr. Chen’s work signifies a shift in how we view the skin. Rather than a sterile barrier or a static environment, the skin is increasingly understood as a dynamic ecosystem that actively manages the immune system. If successful, her work could lead to topical treatments that use beneficial bacteria to "retrain" the immune system, potentially curing chronic skin conditions like psoriasis or atopic dermatitis without the need for systemic immunosuppressants.
2. Precision Therapeutics through Structural Biology
Dr. Peng’s research into GPCRs targets the "control center" of human physiology. By observing these receptors in real-time at the single-molecule level, we move closer to "precision pharmacology." Instead of developing drugs that indiscriminately affect a receptor, scientists could design molecules that lock receptors into specific, therapeutic configurations, minimizing side effects and increasing efficacy.
3. Democratizing Drug Discovery for Rare Diseases
Perhaps the most ambitious project is Dr. Neal’s "Encore." By attempting to screen 1.6 million drug-disease combinations, he is essentially proposing an automated, systemic solution to the "orphan drug" problem. Rare diseases are often ignored by pharmaceutical companies due to the high cost of development relative to the small patient populations. If Encore proves successful, it could provide a template for rapidly identifying existing, FDA-approved drugs that can be repurposed for rare conditions, drastically reducing the time and cost required to bring treatments to patients.
Conclusion
The recognition of Erin Chen, Sam Peng, and JT Neal by the NIH serves as a powerful reminder of the importance of funding curiosity-driven, high-impact science. As these researchers begin their work, the scientific community looks on with anticipation. Their projects represent more than just academic achievement; they represent a bold, calculated bet on the future of medicine—a future where the invisible is visualized, the microbial is managed, and the rarest of diseases finally find a path to treatment.
Through the support of the NIH High-Risk, High-Reward program, the Broad Institute continues to prove that when scientists are given the resources to pursue unconventional paths, the results can redefine the boundaries of human knowledge and patient care.
About the Author
